Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma
<p><strong>Background:</strong> An important proportion of asthma patients remain uncontrolled despite using inhaled corticosteroids and long-acting beta-agonists. Clinical guidelines recommend, in these patients, using add-on long-acting muscarinic antagonists (triple therapy) to...
| Main Authors: | , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado em: |
BioMed Central
2021
|